Edition:
United Kingdom

Smith & Nephew PLC (SN.L)

SN.L on London Stock Exchange

1,721.50GBp
4:35pm BST
Change (% chg)

18.00 (+1.06%)
Prev Close
1,703.50
Open
1,699.50
Day's High
1,721.50
Day's Low
1,693.00
Volume
2,007,251
Avg. Vol
2,187,061
52-wk High
1,721.50
52-wk Low
1,242.50

Latest Key Developments (Source: Significant Developments)

Smith & Nephew Launches Conquest FN Femoral Neck Fracture System
Wednesday, 5 Jun 2019 

June 5 (Reuters) - Smith & Nephew PLC ::SMITH & NEPHEW LAUNCHES CONQUEST FN™ FEMORAL NECK FRACTURE SYSTEM.  Full Article

Smith & Nephew's Q1 Revenue Rises To $1.2 Bln
Thursday, 2 May 2019 

May 2 (Reuters) - Smith & Nephew Plc ::Q1 REVENUE ROSE 4.4 PERCENT TO 1.202 BILLION USD.Q1 REVENUE OF $1,202 million (2018: $1,196 MILLION), UP 4.4 PCT ON AN UNDERLYING BASIS (0.5 PCT REPORTED GROWTH AFTER -3.9 PCT FOREIGN EXCHANGE HEADWIND).2019 GUIDANCE UPDATED.INCREASINGLY CONFIDENT THAT 2019 UNDERLYING REVENUE GROWTH WILL BE IN UPPER HALF OF GUIDANCE RANGE OF 2.5 PCT TO 3.5 PCT.EXPECTED TRADING PROFIT MARGIN UNCHANGED IN RANGE OF 22.8 PCT TO 23.2 PCT.2019 GUIDANCE IS FOR YEAR-ON-YEAR IMPROVEMENT IN UNDERLYING REVENUE GROWTH AND TRADING PROFIT MARGIN.CONTINUE TO EXPECT 2019 TRADING PROFIT MARGIN TO BE IN RANGE OF 22.8 PCT TO 23.2 PCT.2019 REPORTED REVENUE GROWTH RATE IS EXPECTED TO BE IN RANGE OF 2.9 PCT TO 3.9 PCT.  Full Article

Smith & Nephew In Talks To Buy Nuvasive For Over $3 Bln- FT
Friday, 8 Feb 2019 

Feb 8 (Reuters) - :SMITH & NEPHEW IN TALKS TO BUY NUVASIVE FOR OVER $3 BILLION- FT.  Full Article

Smith & Nephew Acquires Ceterix Orthopaedics
Tuesday, 22 Jan 2019 

Jan 22 (Reuters) - Smith & Nephew PLC ::SMITH & NEPHEW PLC - SMITH & NEPHEW ACQUIRES CETERIX ORTHOPAEDICS.SMITH & NEPHEW - COMPLETED ACQUISITION OF CETERIX ORTHOPAEDICS; COST OF DEAL IS $50 MILLION AND UP TO A FURTHER $55 MILLION OVER NEXT FIVE YEARS.  Full Article

Smith & Nephew Says Expects To Meet FY Forecast
Monday, 7 Jan 2019 

Jan 7 (Reuters) - Smith & Nephew PLC ::CONFIRMS THAT IT EXPECTS TO MEET ITS 2018 FULL YEAR GUIDANCE.  Full Article

ConforMIS Announces Settlement Of Patent Dispute With Smith & Nephew
Monday, 17 Sep 2018 

Sept 17 (Reuters) - ConforMIS Inc ::CONFORMIS ANNOUNCES SETTLEMENT OF PATENT DISPUTE WITH SMITH & NEPHEW.CONFORMIS - SMITH & NEPHEW IS REQUIRED TO PAY $10.5 MILLION TO CO & PARTIES ENTERED INTO A LIMITED PATENT CROSS-LICENSE​.CONFORMIS - SETTLEMENT AND LICENSE AGREEMENT WITH SMITH & NEPHEW RESOLVES ALL PATENT DISPUTES BETWEEN CO AND SMITH & NEPHEW.  Full Article

Conformis Announces Settlement Of Patent Dispute With Smith & Nephew
Monday, 17 Sep 2018 

Sept 17 (Reuters) - ConforMIS Inc ::CONFORMIS ANNOUNCES SETTLEMENT OF PATENT DISPUTE WITH SMITH & NEPHEW.CONFORMIS - SETTLEMENT AND LICENSE AGREEMENT WITH SMITH & NEPHEW RESOLVES ALL PATENT DISPUTES BETWEEN CO AND SMITH & NEPHEW.CONFORMIS - SMITH & NEPHEW IS REQUIRED TO PAY $10.5 MILLION TO CO, AND PARTIES ENTERED INTO A LIMITED PATENT CROSS-LICENSE​.CEDAR REALTY TRUST INC SAYS SEXUAL HARASSMENT LAWSUIT AGAINST CEO BRUCE SCHANZER DISMISSED​.  Full Article

Smith & Nephew Announces Full Commercial Release Of Journey II XR Total Knee Arthroplasty​
Tuesday, 6 Mar 2018 

March 6 (Reuters) - Smith & Nephew Plc ::SMITH & NEPHEW PLC - ANNOUNCES FULL COMMERCIAL RELEASE OF JOURNEY II XR TOTAL KNEE ARTHROPLASTY​.  Full Article

Smith & Nephew announces acquisition of Rotation Medical Inc​
Wednesday, 6 Dec 2017 

Dec 6 (Reuters) - SMITH & NEPHEW PLC ::ACQUISITION OF ROTATION MEDICAL INC​.‍ACQUISITION COST IS $125 MILLION AND UP TO A FURTHER $85 MILLION OVER NEXT FIVE YEARS, CONTINGENT ON FINANCIAL PERFORMANCE​.  Full Article

S&N CEO will not confim if activist investor Elliott has stake
Friday, 3 Nov 2017 

Nov 3 (Reuters) - Smith & Nephew :Ceo says cost savings plan will be finalised by year-end results in feb.Ceo will not comment on identity of any investors.Ceo says not thinking about asset disposal at all.Ceo says he will until last day of his tenure, transition will be smooth.Ceo says impact of us. Hurricanes was about $5 million, also affected emerging markets.Ceo says he confident in existing company strategy, pursuing ongoing simplification.Ceo says he is not pushing for m&a, believe startegy will create value for all shareholders.  Full Article

Photo

Will Europe's clampdown on faulty medical devices hurt patients?

BERLIN When a Californian company founded by a U.S. veteran wounded in Afghanistan sought to register a new medical device this year, it turned to Europe before the United States. The European approvals system had long been quicker, the company said, but the introduction of new rules is changing all that.